• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Tuesday

    6/13/23 1:44:11 PM ET
    $AUMN
    $BBIG
    $BENF
    $BIOC
    Precious Metals
    Basic Materials
    Recreational Games/Products/Toys
    Consumer Discretionary
    Get the next $AUMN alert in real time by email

     

    On Tuesday, 32 companies reached new 52-week lows.

    Key Facts About Today's 52-Week Lows:

    • Vodafone Group (NASDAQ:VOD) is the largest company in terms of market cap to set a new 52-week low this morning.
    • The smallest company by market cap to set a new 52-week low was Nova Lifestyle (NASDAQ:NVFY).
    • OceanPal (NASDAQ:OP)'s stock made the biggest move downwards, diving 26.32% to reach a new 52-week low.
    • EBET (NASDAQ:EBET) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low.

    On Tuesday, the following stocks hit new 52-week lows:

    • Vodafone Group (NASDAQ:VOD) stock hit a new 52-week low of $9.00. The stock was down 0.49% on the session.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) shares made a new 52-week low of $124.58 on Tuesday. The stock was up 0.31% for the day.
    • Indivior (NASDAQ:INDV) shares set a new 52-week low of $21.71. The stock traded down 2.99%.
    • Beneficient (NASDAQ:BENF) shares set a new 52-week low of $5.65. The stock traded down 11.77%.
    • Oxford Square Cap (NASDAQ:OXSQ) stock hit a yearly low of $2.69. The stock was down 0.44% for the day.
    • Alaunos Therapeutics (NASDAQ:TCRT) stock achieved a new 52-week low on Tuesday morning, hitting $0.45 and moving up 2.25%.
    • Mullen Automotive (NASDAQ:MULN) shares fell to $0.33 on Tuesday, setting a new 52-week low with a shift of down 12.62%.
    • Integra Resources (AMEX:ITRG) stock hit a new 52-week low of $0.95. The stock was down 0.21% on the session.
    • Powerbridge Technologies (NASDAQ:PBTS) stock hit a yearly low of $1.30. The stock was up 0.01% for the day.
    • Enochian BioSciences (NASDAQ:ENOB) shares hit a yearly low of $0.62. The stock was down 6.51% on the session.
    • Iridex (NASDAQ:IRIX) stock set a new 52-week low of $1.84 on Tuesday, moving up 3.17%.
    • Vinco Ventures (NASDAQ:BBIG) stock achieved a new 52-week low on Tuesday morning, hitting $1.88 and moving down 4.51%.
    • Golden Minerals (AMEX:AUMN) stock hit a new 52-week low of $2.04. The stock was down 7.17% on the session.
    • Precipio (NASDAQ:PRPO) shares were down 1.72% for the day, having made a 52-week low of $0.43.
    • Greenidge Generation Hldg (NASDAQ:GREE) stock set a new 52-week low of $1.55 on Tuesday, moving down 3.3%.
    • Tenon Medical (NASDAQ:TNON) stock hit a new 52-week low of $0.70. The stock was down 5.11% on the session.
    • Plus Therapeutics (NASDAQ:PSTV) shares moved down 1.29% on Tuesday to hit a new 52-week low of $3.02, drifting down 1.29%.
    • Cyxtera Technologies (NASDAQ:CYXT) shares hit a yearly low of $0.04. The stock was down 11.37% on the session.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares made a new 52-week low of $2.48 on Tuesday. The stock was down 3.7% for the day.
    • EBET (NASDAQ:EBET) shares set a new yearly low of $0.19 this morning. The stock was 0.0% (flat) on the session.
    • iMedia Brands (NASDAQ:IMBI) stock hit a new 52-week low of $0.16. The stock was down 7.8% on the session.
    • BiondVax Pharmaceuticals (NASDAQ:BVXV) shares fell to $1.29 on Tuesday, setting a new 52-week low with a shift of down 1.73%.
    • Greenlane Hldgs (NASDAQ:GNLN) shares hit a yearly low of $2.10. The stock was down 4.5% on the session.
    • OceanPal (NASDAQ:OP) stock achieved a new 52-week low on Tuesday morning, hitting $2.56 and moving down 26.32%.
    • Biocept (NASDAQ:BIOC) stock achieved a new 52-week low on Tuesday morning, hitting $1.76 and moving down 1.6%.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $AUMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUMN
    $BBIG
    $BENF
    $BIOC

    CompanyDatePrice TargetRatingAnalyst
    Jazz Pharmaceuticals plc
    $JAZZ
    4/10/2026$227.00Outperform
    Raymond James
    Jazz Pharmaceuticals plc
    $JAZZ
    2/27/2026$224.00Overweight
    Barclays
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Vodafone Group Plc
    $VOD
    1/7/2026Hold → Buy
    Berenberg
    Integra Resources Corp.
    $ITRG
    12/8/2025$5.75Buy
    Roth Capital
    Vodafone Group Plc
    $VOD
    12/8/2025Equal Weight → Overweight
    Barclays
    Jazz Pharmaceuticals plc
    $JAZZ
    11/24/2025$188.00Buy → Neutral
    UBS
    Vodafone Group Plc
    $VOD
    11/3/2025Neutral → Sell
    UBS
    More analyst ratings

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Daniels Eric Joseph

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    4/22/26 5:00:04 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Daniels Eric Joseph

    3 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    4/21/26 5:00:06 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Hicks Mack H.

    3 - Beneficient (0001775734) (Issuer)

    4/20/26 7:01:44 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ryan Barbara bought $249 worth of shares (8 units at $31.09), increasing direct ownership by 0.14% to 5,724 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/13/26 4:25:33 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kingsley Stuart A bought $29,953 worth of shares (940 units at $31.86), increasing direct ownership by 20% to 5,582 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/11/26 9:54:36 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara bought $1,009 worth of shares (31 units at $32.56), increasing direct ownership by 0.55% to 5,716 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/11/26 8:12:31 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James resumed coverage on Jazz Pharma with a new price target

    Raymond James resumed coverage of Jazz Pharma with a rating of Outperform and set a new price target of $227.00

    4/10/26 12:21:53 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Jazz Pharma with a new price target

    Barclays initiated coverage of Jazz Pharma with a rating of Overweight and set a new price target of $224.00

    2/27/26 8:31:30 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $AUMN
    $BBIG
    $BENF
    $BIOC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

    For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

    8/12/21 4:25:43 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUMN
    $BBIG
    $BENF
    $BIOC
    SEC Filings

    View All

    SEC Form 6-K filed by Integra Resources Corp.

    6-K - Integra Resources Corp. (0001722387) (Filer)

    4/23/26 4:26:43 PM ET
    $ITRG
    Precious Metals
    Basic Materials

    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    4/21/26 8:30:16 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Beneficient

    SCHEDULE 13D/A - Beneficient (0001775734) (Subject)

    4/20/26 7:49:20 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

    A collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional outcomes—beyond abstinence aloneOf all MOUD, monthly extended-release buprenorphine (BUP-XR) accounted for the smallest proportion of non-fatal and fatal OD events compared to no treatment. RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), a leader in the treatment of opioid use disorder (OUD), will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine (ASAM) Annual Conference, held April 23-26, 2026, in San

    4/24/26 11:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    INTEGRA ANNOUNCES FIRST QUARTER PRODUCTION RESULTS FROM THE FLORIDA CANYON MINE AND STRENGTHENED BALANCE SHEET

    TSXV: ITR; NYSE American: ITRG www.integraresources.comVANCOUVER, BC, April 23, 2026 /CNW/ - Integra Resources Corp. ("Integra" or the "Company") (TSXV:ITR) (NYSE:ITRG) is pleased to provide an interim operational update for the first quarter ended March 31, 2026 (the "first quarter 2026" or "Q1 2026") highlighting continued operational momentum, record mining rates, and a strengthened balance sheet. The Company plans to release its first quarter 2026 financial results after market close on Monday May 11, 2026, followed by a conference call hosted by senior management on Tuesday

    4/23/26 4:05:00 PM ET
    $ITRG
    Precious Metals
    Basic Materials

    Two Metals, One Junior: NevGold Delivers 99% Gold Recovery, 1.11% Antimony Intercepts, and a C$42.2M Upsized Financing in Three Weeks

    NevGold Corp. (TSXV:NAU, OTCQX:NAUFF, FRA: 5E50)) advances a dual-metal production thesis at Limousine Butte (Nevada) and Nutmeg Mountain (Idaho) — pairing a U.S. Critical Mineral (antimony) and a safe-haven commodity at multi-year highs (gold) — with a maiden antimony-gold Mineral Resource Estimate targeted for Q2 2026 and near-term production targeted for 2027. Companies mentioned in this article: NevGold Corp. (TSXV:NAU, OTCQX:NAUFF, FRA: 5E50)), Orla Mining Ltd. (NYSE:ORLA), Integra Resources Corp. (NYSE:ITRG), Military Metals Corp. (OTCQB:MILIF), Critical Metals Corp. (NASDAQ:CRML) Key Takeaways: NevGold upsized its brokered private placement to C$42,225,497 on April 20, 2026 (22,22

    4/23/26 12:35:00 PM ET
    $CRML
    $ITRG
    $ORLA
    Metal Mining
    Basic Materials
    Precious Metals

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026. The awards were granted on April 20, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist of options to purchase 20,000 shares of the Company common

    4/22/26 4:30:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

    HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR), effective April 13th, 2026. Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutic

    4/15/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

    HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the appointment of Eric J. Daniels, M.D., MBA, as Chief Development Officer, effective April 20, 2026. Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most recently served as Chief Development Officer at Kiora Pharmaceuticals , where he oversaw the company's full development portfolio

    4/9/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OceanPal Inc.

    SC 13D/A - OceanPal Inc. (0001869467) (Subject)

    12/2/24 4:18:52 PM ET
    $OP
    Marine Transportation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by OceanPal Inc.

    SC 13D/A - OceanPal Inc. (0001869467) (Subject)

    12/2/24 4:17:41 PM ET
    $OP
    Marine Transportation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by OceanPal Inc.

    SC 13D/A - OceanPal Inc. (0001869467) (Subject)

    12/2/24 4:13:58 PM ET
    $OP
    Marine Transportation
    Consumer Discretionary

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

    HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ. With SpectronRx serving as a second GMP manufacturing site alongside Radiomedix, and Rhenium-186 isotope supplied through Telix Pharmaceuticals, Plus strengthens the reliability of its multi-partner supply chain

    4/23/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Oxford Square Capital Corp. Schedules First Quarter 2026 Earnings Release and Conference Call for April 29, 2026

    GREENWICH, Conn, April 22, 2026 (GLOBE NEWSWIRE) -- Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NASDAQ:OXSQG) (NASDAQ:OXSQH) announced today that it will hold a conference call to discuss first quarter 2026 earnings on Wednesday, April 29, 2026 at 9:00 AM Eastern time. The toll free dial-in number is 1-800-715-9871, access code number 2511724. There will be a recorded replay of the call available for 30 days after the call. If you are interested in hearing the recording, please dial 1-800-770-2030. The replay pass-code is 2511724#. About Oxford Square Capital Corp.Oxford Square Capital Corp. is a publicly-traded business development company principally investing in syndicated bank loans

    4/22/26 5:24:16 PM ET
    $OXSQ
    Blank Checks
    Finance

    Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026

    DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update.Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.A replay of the webcast will be available via the Investors section of

    4/21/26 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care